Migraine Drugs Market Share

Global Migraine Drugs Market Overview

Migraine Drugs Market Size was valued at USD 5.1 Billion in 2022. The migraine drugs market industry is projected to grow from USD 5.28 Billion in 2023 to USD 7.041 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.65% during the forecast period (2023 - 2032). The market for migraine drugs is driven by an increase in migraine prevalence. Additionally, a rise in female population and a rise in patient awareness of migraine prevention and treatment are major market drivers of market expansion.Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Migraine Drugs Market Trends

• Rising prevalence of migraine around the world is driving the market growth

The rising prevalence of migraine around the world is one of the main reasons anticipated to boost the growth of the  market CAGR for migraine drugs during the forecast period. For instance, migraine and other headache disorders are the second-leading cause of years lived with disability (YLD) in both men and women worldwide. Migraine is one of the most common neurologic conditions, according to the National Centre for Biotechnology Information, with a significant frequency and morbidity, especially in young people and women. Every year, it has an impact on more than a billion people worldwide. As a result, the need for migraine medications is increasing.

The increased public awareness of migraines and available treatments is another factor propelling the expansion of the biosurgery market. For instance, approximately a billion individuals worldwide suffer from migraines, a chronic neurological ailment. People are becoming more aware of migraines, which is driving up demand for migraine treatments. The first week of September is designated as Migraine Awareness Week in the United Kingdom each year. It will be observed from September 4 to September 13 in 2023. The National Migraine and Headache Awareness Month (MHAM)'s official color is purple.

Significant development prospects for competitors in the migraine drugs market are anticipated as demand for safe and effective treatment increases around the globe. For instance, as awareness of migraines grows along with its burden, so too does the demand for safe and effective treatment. Elyxyb (celecoxib oral solution), a novel fast-acting liquid medication, was announced by BioDelivery Sciences for release in January 2022. One of the first adult ready-to-use oral solutions for the treatment of migraine, with or without aura, that the U.S. Food and Drug Administration (FDA) has approved is elyxyb. In turn, this is propelling market expansion. Increased  research and development (R&D) is anticipated to present participants in the migraine drugs market with considerable potential prospects. For instance, Novartis stated in April 2020 that clinical data for Aimovig (erenumab) was published in Neurology. Benefits shown in clinical studies of Aimovig are supported by real-world data. These findings support the use of Aimovig as a migraine prevention strategy and attest to its long-term efficacy and safety in treating individuals with episodic and chronic migraine. This is then anticipated to accelerate the expansion of the  market for migraine treatments. Thus, driving the migraine drugs market revenue.

Migraine Drugs Market Segment Insights

Migraine Drugs End-User Insights

The  migraine drugs market segmentation, based on end-user includes Hospitals and Clinics, Retail Pharmacy, Online Pharmacy and Others. The retail pharmacy segment dominated the market. The main causes of this are an increase in migraine frequency and a rise in demand for over-the-counter (OTC) migraine drugs. The demand for migraine drugs is also predicted to rise as a result of the convenience and accessibility offered by retail pharmacies in this market segment, which are located in residential areas and open for longer hours.

Migraine Drugs Type Insights

The  migraine drugs market segmentation, based on type, includes Episodic Migraine and Chronic Migraine. The episodic migrane category generated the most income. A person with episodic migraine experiences headaches with migraine symptoms 0–14 days per month. An episodic migraine sufferer might not experience attacks every month. This is occasionally referred to as a low-frequency migraine.

Figure 1  Migraine Drugs Market, by Type, 2022 & 2032 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Migraine Drugs Treatment Type Insights

The  migraine drugs market segmentation, based on treatment type, includes Acute, Preventive, and Neuromodulation Devices. The preventive category generated the most income. It is a method of treating migraines that aims to lessen the frequency and intensity of attacks. Off-label and generic antihypertensives, especially beta-blockers like propranolol and atenolol, are prescribed as part of preventive prophylactic therapy. Regular, daily use of preventive medications can lessen migraine frequency or severity. The use of symptom-relieving medications during migraine attacks is enhanced by preventive treatments.

Migraine Drugs Drug Class Insights

The  migraine drugs market segmentation, based on drug class, includes Triptans, Betablockers, Angiotensin Blockers, Tricyclics and Anticonvulsants. The triptans category generated the most income. The efficacy and safety of triptans have been established over time, leading to high acceptance rates and an increase in product demand, which has assisted the market's revenue growth. Triptans reduce the pain associated with migraines by activating serotonin receptors in the brain, which reduce inflammation and constrict blood vessels.

Migraine Drugs Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American migraine drugs market area will dominate this market. The rising incidence of migraines and the greater usage of innovative treatments are both expected to lead to market growth in this area. The United States is playing a vital role in the tremendous growth of the North American market. There is a significant need for effective and safe treatments due to the high prevalence of migraine in the country. Leading pharmaceutical businesses are also present in this market, which is another element boosting its expansion. There are an increasing number of clinical studies being conducted for innovative drugs.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2  MIGRAINE DRUGS MARKET SHARE BY REGION 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe migraine drugs market accounts for the second-largest market share. There is a growing demand for effective treatment alternatives because migraines are so common there. As more clinical studies are conducted and new drugs are released, it is projected that the market in this area will grow. The United Kingdom contributes significantly to the growth of the European market due to the presence of renowned pharmaceutical companies and expanding R&D activity. Further, the German migraine drugs market held the largest market share, and the UK migraine drugs market was the fastest growing market in the European region

The Asia-Pacific Migraine drugs Market is expected to grow at the fastest CAGR from 2023 to 2032. The area has a large population, and the prevalence of migraines is rapidly increasing. Due to rising disposable income and a growing uptake of Western lifestyles in this region, it is projected that the market would expand. The growth of the Asia Pacific market is mostly attributable to countries like China and India. There is a huge demand for effective, affordable treatments because migraines are quite prevalent throughout the world. Moreover, China’s migraine drugs market held the largest market share, and the Indian migraine drugs market was the fastest growing market in the Asia-Pacific region.

Migraine Drugs Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the migraine drugs market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, migraine drugs industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  migraine drugs industry to benefit clients and increase the market sector. In recent years, the migraine drugs industry has offered some of the most significant advantages to market. Major players in the migraine drugs market attempting to increase market demand by investing in research and development operations include Allergan Plc (Ireland), Alder Biopharmaceuticals Inc. (US), Pfizer Inc. (US), GlaxoSmithKline Plc (UK), Merck & Co. Inc. (US),  Teva Pharmaceutical Industries Ltd (Israel), AstraZeneca PLC (UK), Johnson & Johnson Services Inc. (US), Amgen Inc. (US) and Eli Lilly and Company.

Amgen Inc. (Amgen) is a biotechnology firm that finds, develops, produces, and sells cutting-edge human pharmaceuticals to treat patients with severe diseases. It creates innovative treatments for conditions related to the cardiovascular system, oncology/hematology, inflammation, bone health, neurological problems, and nephrology. The business creates products employing cutting-edge human genetics to comprehend the basics of human biology and assess the challenges of disease. In the US, Amgen mostly sells its goods to wholesale distributors of pharmaceuticals.

The research, development, manufacture, and marketing of prescription medications, biologic treatments, vaccines, and animal health products are the sole focus of the biopharmaceutical company Merck & Co Inc (Merck). For the treatment of illnesses including diabetes, cancer, immunological disorders, cardiovascular disease, and cancer, it offers medications that may be obtained with a prescription. In addition to other animal health products, the company sells goods for poultry, cattle, and aquaculture. Hospitals, government agencies, distributors, retailers, and hospitals are among the clients of Merck's managed healthcare services. Additionally, it offers animal health products to distributors, producers, and veterinarians.

Key Companies in the migraine drugs market include

• Allergan Plc (Ireland)


• Alder Biopharmaceuticals Inc. (US)


• Pfizer Inc. (US)


• GlaxoSmithKline Plc (UK)


• Merck & Co. Inc. (US)


• Teva Pharmaceutical Industries Ltd (Israel)


• AstraZeneca PLC (UK)


• Johnson & Johnson Services Inc. (US)


• Amgen Inc. (US)


• Eli Lilly and Company

Migraine Drugs Industry Developments

February 2022 The calcitonin gene-related peptide (CGRP) receptor antagonist Rimegepant received a favorable opinion from the European Medicines Agency (EMA), according to reports from Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. The oral dissolving tablet form of Rimegepant, which comes in a 75 mg dose, is advised for use in episodic migraine prevention in adults who experience at least four migraine attacks per month as well as the acute treatment of migraine with or without aura in adults.

January 2022 Elyxyb (celecoxib oral solution), a novel medicine from BioDelivery Sciences, is a fast-acting liquid. It is one of the first adult ready-to-use oral solutions for the acute treatment of migraine, with or without aura, that has received approval from the Food and Drug Administration.

January 2020 The usage of ubrogepant produced by Allegran was approved by the US FDA. The medication is used to treat severe migraines.

October 2019 Eli Lilly and Company's Reyvow received a 510(k) marketing authorization from the US FDA. The drug is intended to treat migraine in individuals older than 18 years old.

Migraine Drugs Market Segmentation

Migraine Drugs End-User Outlook (USD Billion, 2018-2032)

• Hospitals And Clinics


• Retail Pharmacy


• Online Pharmacy


• Others

Migraine Drugs Type Outlook (USD Billion, 2018-2032)

• Episodic Migraine


• Chronic Migraine

Migraine Drugs Treatment Type  Outlook (USD Billion, 2018-2032)

• Acute


• Preventive


• Neuromodulation Devices

Migraine Drugs Drug Class Outlook (USD Billion, 2018-2032)

• Triptans


• Betablockers


• Angiotensin Blockers


• Tricyclics


• Anticonvulsants

Migraine Drugs Regional Outlook (USD Billion, 2018-2032)

• North America


• US


• Canada


• Europe


• Germany


• France


• UK


• Italy


• Spain


• Rest of Europe


• 
  Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America